[go: up one dir, main page]

TNSN03155A1 - Vaccination unidose avec mycoplasma hyopneumoniae - Google Patents

Vaccination unidose avec mycoplasma hyopneumoniae

Info

Publication number
TNSN03155A1
TNSN03155A1 TNPCT/IB2002/002121A TNSN03155A TNSN03155A1 TN SN03155 A1 TNSN03155 A1 TN SN03155A1 TN SN03155 A TNSN03155 A TN SN03155A TN SN03155 A1 TNSN03155 A1 TN SN03155A1
Authority
TN
Tunisia
Prior art keywords
vaccine
hyo
single dose
mycoplasma hyopneumoniae
dose vaccination
Prior art date
Application number
TNPCT/IB2002/002121A
Other languages
English (en)
Inventor
Robin Lee Keich
Lisa Grace Sabbadini
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23168589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN03155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN03155A1 publication Critical patent/TNSN03155A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/87—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE DES METHODES POUR LE TRAITEMENT OU LA PREVENTION D'UNE MALADIE OU AFFECTION CHEZ UN ANIMAL, PROVOQUEE PAR UNE INFECTION PAR MYCOPLASMA HYOPNEUMONIAE (M.HYO) EN ADMINISTRANT A L'ANIMAL AGE D'APPROXIMATIVEMENT TROIS (3) A DIX (10) JOURS UNE DOSE UNIQUE D'UNE QUANTITE EFFICACE D'UN VACCIN A M.HYO. LE VACCIN A M. HYO PEUT ETRE UNE PREPARATION VIVANTE, INACTIVEE OU MODIFIEE, DE CELLULES ENTIERES OU PARTIELLES, UN VACCIN A SOUS-UNITE, OU UN VACCIN A ACIDE NUCLEIQUE OU VACCIN A ADN. LE VACCIN A M. HYO ADMINISTRE CONFORMEMENT A LA PRESENTE INVENTION PEUT ETRE SYNTHETISE OU PRODUIT PAR RECOMBINAISON.
TNPCT/IB2002/002121A 2001-07-02 2002-06-07 Vaccination unidose avec mycoplasma hyopneumoniae TNSN03155A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30263601P 2001-07-02 2001-07-02

Publications (1)

Publication Number Publication Date
TNSN03155A1 true TNSN03155A1 (fr) 2005-12-23

Family

ID=23168589

Family Applications (1)

Application Number Title Priority Date Filing Date
TNPCT/IB2002/002121A TNSN03155A1 (fr) 2001-07-02 2002-06-07 Vaccination unidose avec mycoplasma hyopneumoniae

Country Status (42)

Country Link
US (3) US6846477B2 (fr)
EP (3) EP1474067B2 (fr)
JP (1) JP2005515162A (fr)
KR (1) KR20040030785A (fr)
CN (3) CN101524532B (fr)
AP (1) AP2003002937A0 (fr)
AR (1) AR034678A1 (fr)
AT (1) ATE412426T2 (fr)
AU (1) AU2002309109B2 (fr)
BG (1) BG66481B1 (fr)
BR (1) BR0210804A (fr)
CA (1) CA2451626C (fr)
CY (1) CY1108749T1 (fr)
CZ (1) CZ305781B6 (fr)
DE (1) DE60229666D1 (fr)
DK (3) DK2842569T3 (fr)
DO (1) DOP2002000431A (fr)
EA (1) EA009901B1 (fr)
ES (3) ES2729579T3 (fr)
GT (1) GT200200138A (fr)
HK (1) HK1207584A1 (fr)
HR (1) HRP20031079A2 (fr)
HU (1) HU230246B1 (fr)
IL (1) IL159349A0 (fr)
IS (1) IS7076A (fr)
MA (1) MA27047A1 (fr)
MX (1) MXPA03011599A (fr)
NO (1) NO342654B1 (fr)
NZ (1) NZ530106A (fr)
OA (1) OA12638A (fr)
PA (1) PA8549701A1 (fr)
PE (1) PE20030285A1 (fr)
PL (1) PL209773B1 (fr)
PT (3) PT2027873E (fr)
SK (1) SK288010B6 (fr)
TN (1) TNSN03155A1 (fr)
TW (1) TWI329514B (fr)
UA (1) UA78707C2 (fr)
UY (1) UY27366A1 (fr)
WO (1) WO2003003941A2 (fr)
YU (1) YU102203A (fr)
ZA (1) ZA200309698B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
WO2006056841A1 (fr) * 2004-11-24 2006-06-01 Pharmacia & Upjohn Company Llc Vaccins multisouches a base de mycoplasma hyopneumoniae
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
HUE054868T2 (hu) * 2005-12-29 2021-10-28 Boehringer Ingelheim Animal Health Usa Inc Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására
EP1976558B1 (fr) 2005-12-29 2017-03-15 Boehringer Ingelheim Vetmedica, Inc. Composition immunogène de pcv2 pour la réduction de symptômes cliniques
CA2644195A1 (fr) * 2006-03-03 2007-09-13 Merial Limited Vaccin contre le mycoplasma hyopneumoniae
US20100136060A1 (en) * 2006-11-22 2010-06-03 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (fr) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Procede efficace de traitement du circovirus porcin et des infections par lawsonia intracellularis
ES2726777T3 (es) 2006-12-15 2019-10-09 Boehringer Ingelheim Animal Health Usa Inc Vacuna porcina anti-PCV2 en dosis única
EP1941903A1 (fr) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxie et traitement du PRDC
EP1958644A1 (fr) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prévention et traitement du PCVD subclinique
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
ME01000B (me) * 2007-11-06 2012-10-20 Zoetis Services Llc Živa vakcina avirulentne mycoplasma hyopneumoniae sa adjuvansom
EP2231182A4 (fr) * 2007-12-31 2012-08-22 Boehringer Ingelheim Vetmed Particule de type virus pcv2 orf2 avec insertion d'acides aminés étrangers
CN101236206B (zh) * 2008-01-17 2014-10-15 中国兽医药品监察所 一种猪肺炎支原体重组抗原elisa检测试剂盒
WO2009126356A2 (fr) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Compositions immunogènes de mycoplasma hyopneumoniae pcv2, et procédés de production de telles compositions
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
LT3056214T (lt) * 2008-06-27 2019-06-10 Zoetis Services Llc Naujos adjuvantų kompozicijos
JP5968622B2 (ja) 2009-06-04 2016-08-10 国立感染症研究所長 マイコプラズマ感染症用ワクチン
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
EP2550362B1 (fr) 2010-03-25 2017-01-04 Oregon Health&Science University Glycoprotéines du cmv et vecteurs recombinés
PL2569007T3 (pl) 2010-05-11 2016-04-29 Intervet Int Bv Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
SG10201604175XA (en) * 2010-07-26 2016-07-28 Qu Biolog Inc Immunogenic anti-inflammatory compositions
CA2808285C (fr) * 2010-08-27 2016-09-06 Intervet International B.V. Test d'activite biologique destine a des formulations de vaccin
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
UA115053C2 (uk) 2012-03-07 2017-09-11 Сева Санте Анімаль Композиція, що містить антиген і ліпополісахарид у формі масло-в-воді, та спосіб її використання (варіанти)
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA121193C2 (uk) 2012-12-28 2020-04-27 Бьорінгер Інгельхайм Ветмедіка Гмбх Спосіб одержання імуногенної композиції проти мікоплазми
JP6195630B2 (ja) 2012-12-28 2017-09-13 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ マイコプラズマ抗原を含む免疫原性組成物
JP6113306B2 (ja) * 2013-02-05 2017-04-12 アグリカルチュラル テクノロジー リサーチ インスティテュート 抗マイコプラズマ属菌種サブユニットワクチン
CN104338125A (zh) * 2013-07-29 2015-02-11 普莱柯生物工程股份有限公司 一种猪肺炎支原体抗原在预防和治疗猪呼吸道疾病综合征方面的应用
WO2015042369A2 (fr) 2013-09-19 2015-03-26 Zoetis Llc Adjuvants à base d'huile
EP3052516B1 (fr) 2013-10-02 2020-01-01 Boehringer Ingelheim Animal Health USA Inc. Variant de protéine orf2 de pcv2 et particules de type viral composées de celui-ci
CN105792841B (zh) * 2013-11-21 2019-07-26 财团法人农业科技研究院 防治霉浆菌感染的组合物
CN105012948B (zh) * 2014-04-18 2019-07-30 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
CN104248753B (zh) * 2014-05-15 2017-07-28 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
DK3244920T5 (da) 2015-01-16 2024-10-07 Zoetis Services Llc Mund- og klovsyge-vaccine
KR20160099223A (ko) * 2015-02-12 2016-08-22 강원대학교산학협력단 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법
US10519199B2 (en) * 2016-08-12 2019-12-31 Innovac Vaccine composition comprising recombinant protein for preventing swine Mycoplasma infection
RU2668799C1 (ru) * 2017-09-08 2018-10-02 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
CN108101969A (zh) * 2017-11-13 2018-06-01 南京大爻网络科技有限公司 一种与猪支原体肺炎相关的抗原及其应用
RU2695679C1 (ru) * 2018-09-11 2019-07-25 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
RU2759427C2 (ru) * 2019-07-08 2021-11-12 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp
CN117305192A (zh) * 2023-12-01 2023-12-29 北京瑞阳瑞泰生物科技有限公司 一种猪肺炎支原体rt02株、疫苗组合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
EP0283840A3 (fr) * 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Antigène de mycoplasma hyopneumoniae et ses utilisations
EP0307976B1 (fr) 1987-09-18 1993-06-23 Akzo Nobel N.V. Vaccin contre mycoplasma
EP0527771A4 (en) 1990-04-02 1993-05-05 Synergen, Inc. Polypeptides useful in diagnosis of and treatment against mycoplasma infections in animals
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
WO1991018627A1 (fr) 1990-05-29 1991-12-12 Smithkline Beecham Corporation Vaccin contre la pneumonie porcine et procede de preparation dudit vaccin
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP0475185A1 (fr) 1990-08-27 1992-03-18 Nippon Flour Mills Co., Ltd. ADN's encodant les antiqèues superficiels de mycoplasma hyopneumonique, fragments d'ADN pour les amorces, peptides recombinants antigéniques et méthode diagnostique de pneumonie mycoplasmale de porc les utilisant
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
AU687750B2 (en) * 1992-09-28 1998-03-05 Wyeth Holdings Corporation Method of enhancing cell mediated immune responses
US5530874A (en) 1993-02-02 1996-06-25 3Com Corporation Network adapter with an indication signal mask and an interrupt signal mask
WO1995009870A1 (fr) 1993-10-07 1995-04-13 Iowa State University Research Foundation, Inc. CARACTERISATION D'ADHESINES DE $i(MYCOPLASMA HYOPNEUMONIAE)
PT1820512E (pt) 1994-05-10 2013-10-09 Boehringer Ingelheim Vetmed Vacina viva modificada melhorada contra brsv
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
ATE272409T1 (de) 1996-09-30 2004-08-15 Univ Arkansas Verfahren zur erzeugung aktiver immunität durch vakzinkonjugate
EP0846468B1 (fr) 1996-12-05 2004-06-09 Akzo Nobel N.V. Mycoplasma synoviae non virulent et vaccin de celui-ci
CA2311759A1 (fr) 1997-11-26 1999-06-03 Tsungdas Hsu Vaccin a base de mycoplasma hyopneumoniae de recombinaison
AU6128900A (en) * 1999-09-29 2001-04-05 Pfizer Products Inc. Nucleic acids and proteins of the mycoplasma hyopneumoniae mph3 gene and uses thereof
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs

Also Published As

Publication number Publication date
KR20040030785A (ko) 2004-04-09
NZ530106A (en) 2007-06-29
CA2451626A1 (fr) 2003-01-16
BG66481B1 (bg) 2015-02-27
NO20035762L (no) 2004-02-02
NO342654B1 (no) 2018-06-25
UA78707C2 (en) 2007-04-25
BG108546A (bg) 2005-02-28
PL209773B1 (pl) 2011-10-31
HRP20031079A2 (en) 2005-10-31
USRE44399E1 (en) 2013-07-30
AR034678A1 (es) 2004-03-03
DK1474067T3 (da) 2008-12-08
WO2003003941A2 (fr) 2003-01-16
PL373367A1 (en) 2005-08-22
US20050013823A1 (en) 2005-01-20
CN101524532A (zh) 2009-09-09
EP1474067B2 (fr) 2017-08-16
EA009901B1 (ru) 2008-04-28
ATE412426T2 (de) 2008-11-15
HK1207584A1 (en) 2016-02-05
GT200200138A (es) 2003-05-15
ES2312580T5 (es) 2017-12-11
SK288010B6 (sk) 2012-10-02
HUP0400434A2 (en) 2007-08-28
DK2842569T3 (da) 2019-05-20
US20030109473A1 (en) 2003-06-12
EP2842569B1 (fr) 2019-04-10
HK1068250A1 (en) 2005-04-29
EP1474067A2 (fr) 2004-11-10
JP2005515162A (ja) 2005-05-26
CN1551781A (zh) 2004-12-01
ES2729579T3 (es) 2019-11-04
PT2842569T (pt) 2019-06-17
EP1474067A4 (fr) 2005-08-10
DK2027873T3 (en) 2015-11-09
WO2003003941A3 (fr) 2004-07-29
PA8549701A1 (es) 2003-01-24
DE60229666D1 (de) 2008-12-11
CZ305781B6 (cs) 2016-03-16
ES2312580T3 (es) 2009-03-01
IL159349A0 (en) 2004-06-01
MXPA03011599A (es) 2005-03-07
ZA200309698B (en) 2014-04-30
CY1108749T1 (el) 2014-04-09
CN101524532B (zh) 2014-03-19
HK1134900A1 (zh) 2010-05-20
AP2003002937A0 (en) 2003-12-31
EP2027873B8 (fr) 2015-11-11
DOP2002000431A (es) 2003-01-15
AU2002309109B2 (en) 2007-12-13
EP2027873B1 (fr) 2015-09-09
HK1180224A1 (zh) 2013-10-18
DK1474067T4 (en) 2017-10-16
PT2027873E (pt) 2015-11-03
TWI329514B (en) 2010-09-01
IS7076A (is) 2003-12-15
EP2027873A1 (fr) 2009-02-25
US6846477B2 (en) 2005-01-25
PT1474067E (pt) 2008-11-14
MA27047A1 (fr) 2004-12-20
CN102872456B (zh) 2016-01-20
YU102203A (sh) 2006-05-25
EP1474067B1 (fr) 2008-10-29
CZ20033466A3 (cs) 2005-06-15
EA200301323A1 (ru) 2005-06-30
HU230246B1 (hu) 2015-11-30
OA12638A (en) 2006-06-15
PE20030285A1 (es) 2003-03-27
CN1551781B (zh) 2013-01-02
UY27366A1 (es) 2003-04-30
EP2842569A1 (fr) 2015-03-04
SK15792003A3 (sk) 2005-09-08
CN102872456A (zh) 2013-01-16
ES2550458T3 (es) 2015-11-10
BR0210804A (pt) 2005-05-03
CA2451626C (fr) 2011-05-31

Similar Documents

Publication Publication Date Title
TNSN03155A1 (fr) Vaccination unidose avec mycoplasma hyopneumoniae
TNSN03154A1 (fr) Vaccin a mycoplasma bovis et methodes pour reduire la pneumonie chez des animaux.
BRPI0413756A (pt) composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica
MA27388A1 (fr) Vaccin pour des infections du systeme respiratoire et du systeme reproducteur chez les bovins
YU99102A (sh) Postupci i kompozicija za oralnu vakcinaciju
BR0211049A (pt) Método de tratamento ou prevenção de doenças ou disfunções e uso de mycoplasma hyopneumoniae
JP2005534752A5 (fr)
KR20090053967A (ko) 웨스트 나일 백신
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
JP2024174906A (ja) 運動系の疾患の治療のために有用な組成物
US20100291115A1 (en) Pharmaceutical composition for the sublingual administration of vaccines, method for the preparation of the same and uses thereof
RU2093177C1 (ru) Препарат "дина" для лечения и профилактики заболеваний млекопитающих, птиц и рептилий
RU2232501C2 (ru) Способ повышения естественной резистентности животных
RU2258501C2 (ru) Способ применения этидия бромистого для лечения пироплазмоза лошадей
FR2507479A1 (fr) Vaccin contre les infections chlamydiennes des animaux d'elevage
RU2165757C1 (ru) Лечебно-профилактическое средство для молодняка сельскохозяйственных животных и птицы
JP2004210769A (ja) 魚類冷水病ワクチン
RU2146532C1 (ru) Способ лечения и профилактики трихофитии и микроспории пушных зверей и мелких плотоядных животных
Stroop Spinal leptomeningeal epidermoid cysts in inbred mouse strains
RU2204899C2 (ru) Способ повышения воспроизводительной способности ремонтных свинок
RU2004118613A (ru) Способ профилактики и лечения дирофиляриоза собак
RU2195938C1 (ru) Способ получения регидратационного средства "регидратон свф"
Lawson et al. ERA strain rabies vaccine: oral vaccination of nonhuman primates
WO2004103408A2 (fr) Composition vaccinale comprenant du phosphate de fer a titre d’adjuvant vaccinal
UA65816A (en) Vaccine velshisan for preventing toxicoinfections caused by clostridium perfringens